1938. CoviLiv™, a Novel Intranasal Live-Attenuated COVID-19 Vaccine Candidate, Induces Robust Humoral and Cellular Immunity in First-In-Human Clinical Trial CDX-CoV-001

BACKGROUND: CoviLiv is a novel intranasal live-attenuated COVID-19 vaccine candidate, derived from SARS-CoV-2/Wuhan that was synthetically engineered utilizing Codagenix’ codon pair deoptimization platform. CDX-CoV-001 was a randomized, double-blind, placebo-controlled dose-escalation study in healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufmann, Johanna K, Wyllie, Keri, Zhao, Yiwen, Tea, Lasmy, Tasker, Sybil, Yeolekar, Leena R, Dhere, Rajeev, Mueller, Steffen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678173/
http://dx.doi.org/10.1093/ofid/ofad500.2469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678173/
http://dx.doi.org/10.1093/ofid/ofad500.2469

Ejemplares similares